Komori
Other Disclosures2160GNI Group Ltd.Pharmaceuticals

Selected for the Financial Times' “High-Growth Companies Asia-Pacific 2026” ranking (the only Japanese pharmaceutical company, sixth time overall)

The Company was ranked 379th in Financial Times and Statista's “High-Growth Companies Asia-Pacific 2026.” It was the only Japanese company in the Pharmaceuticals category and was included in the ranking for the sixth time overall.

Worth reading
48Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
379
rank
Wording
Definitive
How definitive the wording is.

Announced details

Applicable field (uses covered by this announcement)

Pharmaceuticals

What the company reported numerically
Usage history

Sixth inclusion overall

Relationship between the counterparty and the company
GNI Group Ltd.2160
Relationship with the Company

Organizations responsible for selecting companies for and conducting research for the ranking

CounterpartyFinancial Times、Statista

Financial Times is described as a UK newspaper and Statista as a German research company. Other details are Not disclosed.

Award/certification name

High-Growth Companies Asia-Pacific 2026 (Asia-Pacific Fast-Growing Companies Ranking 2026)

Awarding / certifying body

Financial Times and Statista

In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.

Source (materials cited by the company)

High-Growth Companies Asia-Pacific 2026 by Financial Times and Statista

Announced details
ItemDetails
CounterpartyFinancial Times、Statista
Counterparty overviewFinancial Times is described as a UK newspaper and Statista as a German research company. Other details are Not disclosed.
Relationship with the CompanyOrganizations responsible for selecting companies for and conducting research for the ranking
Applicable areaPharmaceuticals
Award/certification nameHigh-Growth Companies Asia-Pacific 2026 (Asia-Pacific Fast-Growing Companies Ranking 2026)
Awarding / certifying bodyFinancial Times and Statista
Usage historySixth inclusion overall
SourceHigh-Growth Companies Asia-Pacific 2026 by Financial Times and Statista
Items this document does not state (10)
Names of Products / Services CoveredContract ValueOffering priceContract DateLaunch dateRegistration number and expiry dateLocationLocation scaleQuantitative EffectsImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Financial Times and Statista selected the top 500 companies from 13 Asia-Pacific countries based on revenue growth (sales growth) from 2021 to 2024.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Selected for the Financial Times' “High-Growth Companies Asia-Pacific 2026” ranking (the only Japanese pharmaceutical company, sixth time overall) | GNI Group Ltd. (2160) timely disclosure | Komori